Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity  Severine Vermeire, Stefan Schreiber,

Slides:



Advertisements
Similar presentations
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis  Konstantinos.
Advertisements

The Role of Psychosocial Care in Adapting to Health Care Reform
Abnormal Liver Tests and Fatty Liver on Ultrasound
Ashwin N. Ananthakrishnan, Millie D. Long, Christopher F
Saurabh Dawra, Vishal Sharma, Usha Dutta 
Flavia D. Mendes, Ayako Suzuki, Schuyler O. Sanderson, Keith D
Volume 138, Issue 2, Pages (February 2010)
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab  William J. Sandborn, Maria T. Abreu, Geert.
Millie D. Long, Bruce E. Sands 
Ruben Hernaez, MD, MPH, PhD  Clinical Gastroenterology and Hepatology 
Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis  Alexander C. Ford, Khurram J. Khan, William.
Celiac Disease and Persistent Symptoms
A Shocking Cystory Clinical Gastroenterology and Hepatology
Volume 133, Issue 1, Pages (July 2007)
Todd H. Baron, MD, Thomas C. Smyrk, MD 
Immune Reconstitution Inflammatory Syndrome of the Small Bowel in a Human Immunodeficiency Virus–Negative Patient  Severin Daum, Christoph Loddenkemper,
Prevalence of Irritable Bowel Syndrome–type Symptoms in Patients With Celiac Disease: A Meta-analysis  Anita Sainsbury, David S. Sanders, Alexander C.
A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of.
Liver Cirrhosis Is Associated With Venous Thromboembolism Among Hospitalized Patients in a Nationwide US Study  Harry Wu, Geoffrey C. Nguyen  Clinical.
Laurent Peyrin-Biroulet, Julián Panés, William J
Stephen A. Harrison, MD, FACP  Clinical Gastroenterology and Hepatology 
Amnon Sonnenberg, MD, MSc, Brent Y. Lee, MD 
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease  Jean–Frédéric Colombel, William.
Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis 
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease  Elana A. Maser, Renata Villela,
Endocuff to Improve Adenoma Detection: Supported by Low-Quality Evidence or Not Supported by High-Quality Evidence?  Yao Zhang, MD, Sheng-Bing Zhao, MD 
Personalizing Colorectal Cancer Screening: A Systematic Review of Models to Predict Risk of Colorectal Neoplasia  Gene K. Ma, Uri Ladabaum  Clinical Gastroenterology.
A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy  Geoffrey M. Forbes, Marian J. Sturm,
A Multibiomarker Risk Score Helps Predict Risk for Barrett’s Esophagus
Endoscopic Therapy for Barrett's Esophagus
Amie L. Harvey, Tommy Yen, Anand Kunda 
Leon P. McLean, Jonathan S. Chun, Raymond K. Cross 
Francisco A. Sylvester, Scott Leopold, Miriam Lincoln, Jeffrey S
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab  Fernando.
Abnormal Liver Tests and Fatty Liver on Ultrasound
Gastroenterology in a New Era of Accountability: Part 2
William D. Leslie  Clinical Gastroenterology and Hepatology 
New Models of Gastroenterology Practice
William J. Sandborn, Stefan Schreiber, Brian G
Volume 132, Issue 1, Pages (January 2007)
Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study  Timna Naftali, Lihi Bar-Lev Schleider,
Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease  Patrick Chamouard, Zoe Richert, Nicolas Meyer, Gabriel Rahmi,
David H. Bruining, William J. Sandborn 
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis  Konstantinos.
Najat Mourra, Nikias Colignon  Clinical Gastroenterology and Hepatology 
Peter Bytzer  Clinical Gastroenterology and Hepatology 
Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging  Konstantinos Karmiris, Didier.
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases  Xavier Roblin, Hubert Marotte, Melanie.
Effects of Different Coping Strategies on Physical and Mental Health of Patients With Irritable Bowel Syndrome  Lilian Dindo, PhD  Clinical Gastroenterology.
Genetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients  Liesbet Henckaerts, Kristel Van Steen, Isabel Verstreken, Isabelle.
Issue Highlights Clinical Gastroenterology and Hepatology
Elizabeth Mileti, Philip Rosenthal, Marion G. Peters 
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials  Edward.
John S. Kane, Olorunda Rotimi, Simon M
Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study  William J. Sandborn, Stefan Schreiber,
Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis  David N. Moskovitz, Gert Van Assche,
Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet 
Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease  Jennifer Jones, Edward V. Loftus, Remo Panaccione,
Walter Reinisch, Jean-Frederic Colombel, William J
Gastrointestinal Tuberculosis: An Unusual Presentation
A 27-Year-Old Woman With Constipation: Diagnosis and Treatment
Christopher Hung, Desmond Leddin 
Coagulation in Liver Disease: A Guide for the Clinician
Issue Highlights Clinical Gastroenterology and Hepatology
Coloduodenal Fistula in Crohn’s Disease
Medical Therapy for Refractory Pediatric Crohn’s Disease
Challenges of NIH Funding for Young Investigators: How the AGA Is Filling the Gap via the AGA Research Foundation  Timothy C. Wang, Rhonda F. Souza  Clinical.
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months  Gary R. Lichtenstein, Ole Ø. Thomsen,
The Role of Psychosocial Care in Adapting to Health Care Reform
Jordan E. Axelrad, Simon Lichtiger, Amrita Sethi 
Presentation transcript:

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity  Severine Vermeire, Stefan Schreiber, William J. Sandborn, Cécile Dubois, Paul Rutgeerts  Clinical Gastroenterology and Hepatology  Volume 8, Issue 4, Pages 357-363 (April 2010) DOI: 10.1016/j.cgh.2010.01.001 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Calculation of positive and negative predictive values for HBI cut point of ≤4 for remission. Clinical Gastroenterology and Hepatology 2010 8, 357-363DOI: (10.1016/j.cgh.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Comparison of the change from baseline in CDAI and HBI scores from PRECiSE 1 and PRECiSE 2. (A) Dashed lines indicate CDAI response with a change in CDAI of ≥100 points and HBI response with a change in HBI score of ≥3 points. The solid line indicates the regression curve. Spearman correlation coefficient, r = 0.878647. (B) Dashed lines indicate CDAI remission at ≤150 points and HBI remission at ≤4 points. The solid line indicates the regression curve. Spearman correlation coefficient, r = 0.813566. Clinical Gastroenterology and Hepatology 2010 8, 357-363DOI: (10.1016/j.cgh.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 ROC analysis for A, HBI-CDAI remission, and B, HBI-CDAI response. AUC, area under the curve. Clinical Gastroenterology and Hepatology 2010 8, 357-363DOI: (10.1016/j.cgh.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions